Biotechnology exchange traded funds have rebounded after the presidential election and could find further strength under a Donald Trump administration.

On the upcoming webcast, Will Trump Make Biotechnology Great Again?, Andrew McDonald, CEO of LifeSci Advisors and Co-Portfolio Manager of the BioShares funds, and Paul Yook, Founder of LifeSci Index Partners, and Co-Portfolio Manager of the BioShares funds, will try to outline biotechnology’s life under President-elect Trump and look to potential opportunities in cutting-edge drug producers.

For instance, the BioShares Biotechnology Clinical Trials Fund (NasdaqGM: BBC) tracks potential up-and-coming biotechnology companies that are in the clinical trials stage, providing investors with the opportunity to gain exposure to a high-growth segment of the global economy.

BBC specifically targets companies that design specialized drugs that range from antivirals, antibiotics and cancer-fighting medicines to gene therapies, cell-based therapies and enzyme replacement therapies are developed in the biotech sector.

Subscribe to our free daily newsletters!
Please enter your email address to subscribe to ETF Trends' newsletters featuring latest news and educational events.